Overcoming Resistance to MAPK Pathway Inhibitors
Menée in vitro, in vivo et sur 77 échantillons tumoraux prélevés sur des patients atteints d'un mélanome, cette étude suggère l'intérêt de cibler une ligase, SMURF2, pour augmenter l'efficacité antitumorale d'un inhibiteur de MEK tel que le selumetinib
The MAPK pathway is one of the most heavily studied pathways in cancer. The MAPK pathway is an important regulator of many processes that are critical to the malignant phenotype, and a variety of genetic alterations that activate the pathway have been detected in many different kinds of cancer. As a result, the development of inhibitors against the pathway has been an active area of investigation for many years...